Increased Risk of Inflammatory Bowel Disease With Anti-CD20 Treatment in Multiple Sclerosis
Swedish Registry Data Links Rituximab to Elevated Inflammatory Bowel Disease Risk in Relapsing-Remitting Multiple Sclerosis A new Swedish population-based cohort study published in JAMA Neurology reveals that anti-CD20 treatment in ... Read More